© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
March 08, 2022
Article
Teva’s launch makes it the first competitor to Revlimid in the United States, but perhaps not the last.
February 23, 2022
Article
Tuznue, which references Roche’s Herceptin, is currently under review for marketing authorization by the EU European Medicines Agency, Canada, and South Korea.
February 07, 2022
Article
The IGBA maintains dialogue with other national, regional, and international bodies to ensure patient access to high-quality, safe, and effective medicines while reducing costs in pharmaceutical care.
February 02, 2022
Article
Xolair, the only currently approved product containing omalizumab, was first approved in 2003. AVT23 is an investigational compound and has not received regulatory approval in any country. Current sales of Xolair are estimated at $3.3 billion.
August 26, 2020
Article
A September 29, 2020, symposium with Sonia T. Oskouei, PharmD, BCMAS, DPLA, of Cardinal Health will explore how to incorporate biosimilars into the treatment of inflammatory conditions.
August 18, 2020
Article
Ali Mcbride, PharmD, MS, BCOP, is taking a lead role in promoting the use and understanding of biosimilars in oncology.
May 23, 2020
Article
Ruth O’Regan, of the University of Wisconsin Carbone Cancer Center, discusses improving the patient discussion on biosimilars, in an interview.
May 07, 2020
Article
With 1 biosimilar launch and expanded indications for another biosimilar so far this year, Teva Pharmaceutical Industries reported higher biosimilar revenues in the first quarter of 2020.
May 06, 2020
Article
Bausch + Lomb has secured the rights to commercialize a ranibizumab biosimilar in the United States and Canada.
May 02, 2020
Article
Amgen saw biosimilar competition eat a larger share of its innovator drug revenue but also earned some biosimilar pocket money of its own.